PharmTech Poll Results: Outsourced or In-house? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Poll Results: Outsourced or In-house?


The question:

If your company uses contract service providers and manufacturers, which function(s) do you typically keep in-house?

Your responses:

  • Discovery research (1 response)
  • Preclinical animal research
  • ADME-tox work
  • Formulation development (1 response)
  • Process development (1 response)
  • Clincial-scale manufacturing through Phase I
  • Clinical-scale manufacturing through Phase II
  • Clinical-scale manufacturing through Phase III
  • Clinical trials
  • Scale-up to commercial manufacturing (2 responses)
  • Commercial-scale manufacturing (2 responses)
  • Fill-finish
  • Other

Do you have any comments on this poll, or would you like to submit your vote? Email us at ptweb@advanstar.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here